Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results from a phase III, randomized, controlled trial (ESTEEM 1)

Authors
Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2014
This article has no abstract
Epistemonikos ID: 5c7e976d650eecf7cfa7677fcee4aa8f5f4bb4e9
First added on: Feb 05, 2025